• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用纳米材料进行癌症治疗与诊断:综述

Utilizing nanomaterials for cancer treatment and diagnosis: an overview.

作者信息

Mukhopadhyay Bageesha, Singh Sudhakar, Singh Avtar

机构信息

Department of Biomedical Engineering, School of Bioengineering & Biosciences, Lovely Professional University, Phagwara, Punjab, 144001, India.

School of Electrical Engineering and Computing (SoEEC), Adama Science and Technology University (AS-TU), 1888, Adama, Ethiopia.

出版信息

Discov Nano. 2024 Dec 24;19(1):215. doi: 10.1186/s11671-024-04128-z.

DOI:10.1186/s11671-024-04128-z
PMID:39718700
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11668726/
Abstract

Cancer is a deadly disease with complex pathophysiological nature and is the leading cause of death worldwide. Traditional diagnosis methods often detect cancer at a considerably critical stage and the conventional methods of treatment like chemotherapy, radiation therapy, targeted therapy, and immunotherapy have several limitations, multidrug resistance, cytotoxicity, and lack of specificity are a few examples. These pose substantial challenge for effective and favourable cancer treatment. The advent of nanotechnology has revolutionized the face of cancer diagnosis and treatment. Nanoparticles, which have a size range of 1-100 nm, are biocompatible and have special optical, magnetic, and electrical capabilities, less toxic, more stable, exhibit permeability and retention effect, and are used for precise targeting. There are several classes of nanoparticles each having their own sets of unique properties. NPs have played an important role in the drug delivery system, overcoming the multi-drug resistance, reducing the side-effects as seen in conventional therapeutic methods and hence able to solve the limitations of conventional methods of diagnosis and treatment. This review discusses the four major classes of nanoparticles (Lipid based NPs, Carbon NPs and Metallic NPs and Polymeric NPs): their discovery and introduction in medical field, unique properties and characteristics, advantages and disadvantages, sub-categories and characteristics of these categories, major area of application in Cancer diagnosis and treatment, and latest methodologies where these are used in cancer treatment.

摘要

癌症是一种具有复杂病理生理性质的致命疾病,是全球主要的死亡原因。传统的诊断方法往往在相当关键的阶段才能检测出癌症,而化疗、放疗、靶向治疗和免疫治疗等传统治疗方法存在一些局限性,例如多药耐药性、细胞毒性和缺乏特异性等。这些都给有效的癌症治疗带来了巨大挑战。纳米技术的出现彻底改变了癌症诊断和治疗的面貌。纳米颗粒的尺寸范围为1至100纳米,具有生物相容性,具备特殊的光学、磁性和电学性能,毒性较小,更稳定,呈现出渗透和滞留效应,可用于精确靶向。纳米颗粒有几类,每类都有其独特的性质。纳米颗粒在药物递送系统中发挥了重要作用,克服了多药耐药性,减少了传统治疗方法中出现的副作用,从而能够解决传统诊断和治疗方法的局限性。本综述讨论了四类主要的纳米颗粒(脂质基纳米颗粒、碳纳米颗粒、金属纳米颗粒和聚合物纳米颗粒):它们在医学领域的发现和引入、独特的性质和特征、优点和缺点、这些类别的子类别和特征、在癌症诊断和治疗中的主要应用领域,以及它们在癌症治疗中使用的最新方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49a6/11668726/8556d3b2f9fe/11671_2024_4128_Fig16_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49a6/11668726/d29c50c05fc7/11671_2024_4128_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49a6/11668726/77e666faf400/11671_2024_4128_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49a6/11668726/b14ac8f40b94/11671_2024_4128_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49a6/11668726/80f7f4078537/11671_2024_4128_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49a6/11668726/6df0df64ebfe/11671_2024_4128_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49a6/11668726/3666d1a39683/11671_2024_4128_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49a6/11668726/4c129b8f999a/11671_2024_4128_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49a6/11668726/e565acd0670f/11671_2024_4128_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49a6/11668726/b803492fe6c0/11671_2024_4128_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49a6/11668726/41513dcaf0ba/11671_2024_4128_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49a6/11668726/da27da403a95/11671_2024_4128_Fig11_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49a6/11668726/4dbcdb89bb15/11671_2024_4128_Fig12_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49a6/11668726/d6bb01942dd5/11671_2024_4128_Fig13_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49a6/11668726/535f7ce4f338/11671_2024_4128_Fig14_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49a6/11668726/9eadb2a6730d/11671_2024_4128_Fig15_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49a6/11668726/8556d3b2f9fe/11671_2024_4128_Fig16_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49a6/11668726/d29c50c05fc7/11671_2024_4128_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49a6/11668726/77e666faf400/11671_2024_4128_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49a6/11668726/b14ac8f40b94/11671_2024_4128_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49a6/11668726/80f7f4078537/11671_2024_4128_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49a6/11668726/6df0df64ebfe/11671_2024_4128_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49a6/11668726/3666d1a39683/11671_2024_4128_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49a6/11668726/4c129b8f999a/11671_2024_4128_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49a6/11668726/e565acd0670f/11671_2024_4128_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49a6/11668726/b803492fe6c0/11671_2024_4128_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49a6/11668726/41513dcaf0ba/11671_2024_4128_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49a6/11668726/da27da403a95/11671_2024_4128_Fig11_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49a6/11668726/4dbcdb89bb15/11671_2024_4128_Fig12_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49a6/11668726/d6bb01942dd5/11671_2024_4128_Fig13_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49a6/11668726/535f7ce4f338/11671_2024_4128_Fig14_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49a6/11668726/9eadb2a6730d/11671_2024_4128_Fig15_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49a6/11668726/8556d3b2f9fe/11671_2024_4128_Fig16_HTML.jpg

相似文献

1
Utilizing nanomaterials for cancer treatment and diagnosis: an overview.利用纳米材料进行癌症治疗与诊断:综述
Discov Nano. 2024 Dec 24;19(1):215. doi: 10.1186/s11671-024-04128-z.
2
Nanoparticles for Cancer Therapy: Current Progress and Challenges.用于癌症治疗的纳米颗粒:当前进展与挑战
Nanoscale Res Lett. 2021 Dec 5;16(1):173. doi: 10.1186/s11671-021-03628-6.
3
Smart Magnetic Drug Delivery Systems for the Treatment of Cancer.用于癌症治疗的智能磁性药物递送系统
Nanomaterials (Basel). 2023 Feb 26;13(5):876. doi: 10.3390/nano13050876.
4
The role of nanoparticles and nanomaterials in cancer diagnosis and treatment: a comprehensive review.纳米颗粒和纳米材料在癌症诊断与治疗中的作用:全面综述
Am J Cancer Res. 2023 Dec 15;13(12):5751-5784. eCollection 2023.
5
The Clinical Translation of Organic Nanomaterials for Cancer Therapy: A Focus on Polymeric Nanoparticles, Micelles, Liposomes and Exosomes.有机纳米材料在癌症治疗中的临床转化:聚焦于聚合物纳米粒子、胶束、脂质体和外泌体。
Curr Med Chem. 2018;25(34):4224-4268. doi: 10.2174/0929867324666170830113755.
6
Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.癌症治疗的靶向纳米医学:迈向克服耐药性的精准医学。
Drug Resist Updat. 2017 Mar;31:15-30. doi: 10.1016/j.drup.2017.05.002. Epub 2017 May 21.
7
Inorganic Nanoparticles for Cancer Therapy: A Transition from Lab to Clinic.无机纳米粒子在癌症治疗中的应用:从实验室到临床的转变。
Curr Med Chem. 2018;25(34):4269-4303. doi: 10.2174/0929867325666171229141156.
8
Revolutionizing Cancer Care: Advances in Carbon-Based Materials for Diagnosis and Treatment.变革癌症治疗:用于诊断和治疗的碳基材料的进展
Cureus. 2024 Jan 18;16(1):e52511. doi: 10.7759/cureus.52511. eCollection 2024 Jan.
9
Nanomedicines for Overcoming Cancer Drug Resistance.用于克服癌症耐药性的纳米药物。
Pharmaceutics. 2022 Aug 1;14(8):1606. doi: 10.3390/pharmaceutics14081606.
10
Multifunctional Nanoparticles in Precise Cancer Treatment: Considerations in Design and Functionalization of Nanocarriers.多功能纳米粒子在精准癌症治疗中的应用:纳米载体设计与功能化的考虑因素。
Curr Top Med Chem. 2020;20(27):2427-2441. doi: 10.2174/1568026620666200825170030.

引用本文的文献

1
Clinical Applications of Targeted Nanomaterials.靶向纳米材料的临床应用
Pharmaceutics. 2025 Mar 17;17(3):379. doi: 10.3390/pharmaceutics17030379.

本文引用的文献

1
Recent Progress of Cement-Based Materials Modified by Graphene and Its Derivatives.石墨烯及其衍生物改性水泥基材料的研究进展
Materials (Basel). 2023 May 17;16(10):3783. doi: 10.3390/ma16103783.
2
Solid Lipid Nanoparticles (SLNs): Advancements in Modification Strategies Toward Drug Delivery Vehicle.固体脂质纳米粒(SLNs):药物传递载体的修饰策略的进展。
Pharm Nanotechnol. 2023;11(2):138-154. doi: 10.2174/2211738511666221026163303.
3
Cation-Free siRNA Micelles as Effective Drug Delivery Platform and Potent RNAi Nanomedicines for Glioblastoma Therapy.
无阳离子 siRNA 胶束作为有效的药物传递平台和有效的胶质母细胞瘤治疗 RNAi 纳米药物。
Adv Mater. 2021 Nov;33(45):e2104779. doi: 10.1002/adma.202104779. Epub 2021 Sep 18.
4
Lipid Nanoparticles─From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement.脂质纳米颗粒——从脂质体到 mRNA 疫苗传递,研究多样性和进展的全景。
ACS Nano. 2021 Nov 23;15(11):16982-17015. doi: 10.1021/acsnano.1c04996. Epub 2021 Jun 28.
5
Advancement in design of nanostructured lipid carriers for cancer targeting and theranostic application.用于癌症靶向和治疗应用的纳米结构脂质载体的设计进展。
Biochim Biophys Acta Gen Subj. 2021 Sep;1865(9):129936. doi: 10.1016/j.bbagen.2021.129936. Epub 2021 May 29.
6
Lipid Nanoparticles as Carriers for Bioactive Delivery.脂质纳米颗粒作为生物活性物质递送载体
Front Chem. 2021 Apr 23;9:580118. doi: 10.3389/fchem.2021.580118. eCollection 2021.
7
Dual Targeting EGFR and STAT3 With Erlotinib and Alantolactone Co-Loaded PLGA Nanoparticles for Pancreatic Cancer Treatment.用负载厄洛替尼和土木香内酯的聚乳酸-羟基乙酸共聚物纳米颗粒双靶向表皮生长因子受体和信号转导与转录激活因子3用于胰腺癌治疗
Front Pharmacol. 2021 Mar 19;12:625084. doi: 10.3389/fphar.2021.625084. eCollection 2021.
8
Antibody-drug nanoparticle induces synergistic treatment efficacies in HER2 positive breast cancer cells.抗体药物纳米颗粒诱导 HER2 阳性乳腺癌细胞协同治疗效果。
Sci Rep. 2021 Apr 1;11(1):7347. doi: 10.1038/s41598-021-86762-6.
9
Trastuzumab: More than a Guide in HER2-Positive Cancer Nanomedicine.曲妥珠单抗:不仅仅是HER2阳性癌症纳米医学的指南
Nanomaterials (Basel). 2020 Aug 26;10(9):1674. doi: 10.3390/nano10091674.
10
Protein-Nanoparticle Interaction: Corona Formation and Conformational Changes in Proteins on Nanoparticles.蛋白质-纳米颗粒相互作用:纳米颗粒上的冠形成和蛋白质构象变化。
Int J Nanomedicine. 2020 Aug 6;15:5783-5802. doi: 10.2147/IJN.S254808. eCollection 2020.